α-GPC + CDP-Choline (Citicoline)α-GPC + CDP-Choline · 胆碱衍生 nootropic

Place · Level 3 · Supplement

胆碱衍生形态 · ACh 前体 · 卒中后认知部分证据 · 健康人证据弱 · ⚠️ 长期 α-GPC > 3 年中风风险信号 (Tasca 2021 韩国全国 N=12k, HR 1.4-1.8)

Two choline derivatives

Stop 1/4

α-GPC vs CDP-choline · 两种胆碱衍生

α-GPC (alpha-glycerylphosphorylcholine) plus CDP-choline (citicoline, cytidine 5′-diphosphocholine) are two choline-derived nootropic supplements that complement the atlas choline story.

Recap (from the atlas choline story):

Choline: essential nutrient (AI men 550 / women 425 mg/day)Functions: phosphatidylcholine synthesis + acetylcholine (ACh) neurotransmitter + one-carbon metabolism (BHMT pathway) + hepatic lipid transport
α-GPC:

Chemistry: glycerylphosphocholine, naturally present in breast milk and brainHigh brain bioavailability (crosses the well)Content: 40% choline + glycerophosphate + partial direct acetylcholine precursorA prescription drug in some European countries for dementia / post-stroke cognitionSold OTC as a nootropic in the US / China
CDP-choline (Citicoline):

Chemistry: cytidine diphosphate choline, an intermediate in / phospholipid synthesisGood brain bioavailabilityContent: 18% choline + 32% cytidine + phosphatePrescription drug in Japan / Europe: Somazina, etc.OTC: 'Cognizin' (a commercial high-purity form used in most cognitive RCTs)
Differences from plain choline (Choline bitartrate / Phosphatidylcholine):

Plain choline: whole-body supplementation (liver / heart / brain all use it), best cost-effectivenessα-GPC / CDP: more brain-targeted, but expensivePhosphatidylcholine (PC, lecithin): also good bioavailability, but more of a membrane component than a nootropic pathwayTMAO risk: high-dose choline (any form) is processed by gut bacteria into TMA, oxidized in the liver to TMAO; some studies link this to cardiovascular risk (covered in the atlas choline + TMG story), with large individual variation
Why atlas covers this section:

The nootropic market is growing fast, and α-GPC + CDP are mainstream single productsClinical evidence is mixed: B-tier for post-stroke cognition and dementia; weak for healthy-person nootropic effectsHeavy marketing around 'memory / focus / brain protection' — atlas goes through the evidence claim by claimNew warning: Tasca 2021 neurology retrospective data suggests long-term α-GPC supplementation (3+ years) may be associated with stroke risk; replication is ongoing, but it can't be ignored

Read story

本站提供科普与一般性建议，不替代医师诊断或处方；有症状或正在服药请咨询合格医师。 Educational content, not medical advice — consult a clinician for diagnosis or treatment.

Back